Cost Effectiveness of Venlafaxine Compared with Generic Fluoxetine or Generic Amitriptyline in Major Depressive Disorder in the UK
- First Online:
- 70 Downloads
Objective: To estimate the cost effectiveness of venlafaxine compared with generic fluoxetine and generic amitriptyline used in major depressive disorder in primary care in the UK.
Methods: A decision-tree model for the treatment of major depressive disorder was constructed using a Delphi panel. The tree was populated with clinical success rates from a pooled analysis of fluoxetine compared with venlafaxine and a clinical trial of amitriptyline compared with venlafaxine using remission as the key endpoint. Where there was insufficient data from clinical trials, the Delphi panel was used. Costs within the tree were taken from contemporary UK sources. Six-monthly costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios were then estimated.
Results: Treatment costs for 6 months were £1530 for venlafaxine, £1539 for fluoxetine and £1558 for amitriptyline (year of costing 2006). Cost effectiveness as assessed by incremental cost per QALY ratio at 8 weeks was £20 600 for venlafaxine compared with fluoxetine, with fluoxetine dominating (being less costly and more effective than) amitriptyline. To test the robustness of the model a Rank Order Stability Assessment was performed that showed that even if fluoxetine and/or amitriptyline were given away free, a scenario starting with venlafaxine would still be the least costly treatment over a 6-month period.
Conclusions: In this model, venlafaxine was shown to be a cost-effective alternative to generic fluoxetine and amitriptyline when used as a first-line therapy. Thus, cost of therapy should not be a barrier to use of venlafaxine as a first-line option in treating major depressive disorder in primary care in the UK.
- 4.Depression (amended). Management of depression in primary and secondary care. NICE Clinical Guideline 23 (amended): April 2007 [online]. Available from URL: http://http://www.nice.org.uk [Accessed 2009 Feb 1]
- 12.Mallick R, Chen J, Entsuah AR, et al. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors and placebo. J Clin Psychiatry 2003; 64(3): 321–30PubMedCrossRefGoogle Scholar
- 13.NHS reference costs 2005–06, Department of Health, Accessed by: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_062884Google Scholar
- 14.Curtis L, Netten A. Unit costs of health & social care 2005. Canterbury. Personal Social Services Research unitGoogle Scholar
- 16.NICE Guidance Electroconvulsive therapy (ECT) (No. 59) 2003 [online]. Available from URL: http://http://www.nice.org.uk/nicemedia/pdf/59ectfullguidance.pdf [Accessed 2009 Feb 1]
- 17.Netten A, Curtis L. Unit costs of health & social care 2003. Canterbury. Personal Social Services Research unitGoogle Scholar
- 18.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised: DSM-III-R. Washington, DC: American Psychiatric Association, 1987Google Scholar
- 19.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., revised: DSM-IV-R. Washington, DC: American Psychiatric Association, 2000Google Scholar
- 20.Nemeroff C, Cantillon M. A comparison of venlafaxine versus fluoxetine or placebo in depressed outpatients. Poster presented at CINP, Brussels, 2000Google Scholar
- 21.Schatzberg A, Cantillon M. Antidepressant early response and remission with venlafaxine or fluoxetine in depressed geriatric outpatients. Poster presented at CINP, Brussels, 2000Google Scholar
- 25.Rudolph R. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. Hamburg: poster presented at World Congress of Psychiatry; 1999Google Scholar
- 26.Kornaat H. Randomised, double-blind comparison of venlafaxine and fluoxetine for moderately depressed out-patients. Poster presented at CINP 1997Google Scholar
- 27.Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomized, 12 week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim Care Psychiatry 1997; 3: 51–58Google Scholar
- 28.Alves C, Cachola I, Brandao J, et al. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry 1999; 5(2): 57–63Google Scholar
- 30.Stevens I. Comparison of the efficacy and safety of venlafaxine and fluoxetine in GP patients with moderate to severe depression. Poster presented at World Congress of Biological Psychiatry 1997Google Scholar
- 31.Stevens I. Comparison of the efficacy and safety of venlafaxine and fluoxetine in GP patients with moderate to severe depression. Poster presented at World Congress of Biological Psychiatry 1997 au31._Ian Anderson. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58(1): 19–36PubMedCrossRefGoogle Scholar